Full Text View
Tabular View
No Study Results Posted
Related Studies
Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery
This study is currently recruiting participants.
Verified by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), September 2009
First Received: October 27, 2006   Last Updated: September 1, 2009   History of Changes
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator: University of Arkansas
Information provided by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier: NCT00393848
  Purpose

The purpose of this study is to determine the effects of two postoperative interventions designed to preserve muscle protein after major hip or knee surgery.


Condition Intervention Phase
Hip Fracture
Osteoarthritis
Femur Head Necrosis
Drug: Essential amino acid supplement
Drug: Ketoconazole
Drug: Whey protein
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Restoration of Muscle Following Hip Surgery

Resource links provided by NLM:


Further study details as provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):

Primary Outcome Measures:
  • Muscle protein synthesis [ Time Frame: measured after hospitalization ] [ Designated as safety issue: No ]
  • Muscle protein breakdown [ Time Frame: measured after hospitalization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Functional outcomes [ Time Frame: measured prior to surgery, then 2 weeks and 6-8 weeks after discharge ] [ Designated as safety issue: No ]
  • Muscle mass [ Time Frame: measured prior to surgery, then 2 weeks and 6-8 weeks after discharge ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: October 2006
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Essential amino acid supplement
    15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
    Drug: Ketoconazole
    200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
    Drug: Whey protein
    15g of whey protein in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
Detailed Description:

Hip fractures among the elderly are a major health concern. Nearly one-third of elderly hip fracture patients die within 1 year of the injury. Events surrounding the actual injury and any necessary surgical repair often lead to reduced muscle protein, and eventually, muscle strength. Loss in everyday function and independence may follow, especially in elderly or frail individuals. The decrease in protein synthesis may be caused by two main events following injury and surgery: prolonged inactivity and an increase in stress hormone levels. Preventing a loss in protein may help to improve outcomes for individuals undergoing hip surgery and rehabilitation. The purpose of this study is to determine the effects of two postoperative interventions designed to retain muscle protein after major hip or knee surgery in adults.

This study will include two experiments. Experiment 1 will include individuals who are scheduled for hip or knee replacement surgery because of osteoarthritis (the need to repair or replace the affected joint), or avascular necrosis (bone tissue death caused by lack of blood supply). Experiment 1 participants will be randomly assigned to one of four groups:

  • Group 1 participants will receive daily supplements of essential amino acids, which are thought to stimulate protein synthesis.
  • Group 2 participants will receive daily supplements of whey, an intact protein that has been considered less effective than essential amino acids at stimulating protein synthesis.
  • Group 3 participants will receive daily lactose monohydrate, which will act as an equivalent caloric control.
  • Group 4 participants will receive standard rehabilitation care while in the hospital and will serve as controls for the effect of time on recovery.

Participants will be in the hospital for about 4 days. On the morning of surgery, blood and urine collection will occur. During surgery, substances called tracers, measuring the extent of protein synthesis and breakdown, will be injected into a vein for the first metabolic study. Additional blood and muscle samples will also be taken. After surgery, when participants arrive in the surgical recovery unit and are able to eat, they will begin to record all food intake and will receive their assigned treatment. Treatment, in the form of gel capsules, will be taken 2.5 hours after each meal. Urine will be collected throughout hospitalization and blood will be collected each morning. Prior to discharge, a 24-hour metabolic study will be performed, including tracer injections and muscle biopsies. After discharge, participants will be provided with 6 weeks' worth of their assigned treatment. Follow-up visits will occur 2 and ~6 to 8 weeks after surgery. These visits will include various muscle function and physical performance tests. Participants will also undergo a dual energy x-ray absorptiometry (DEXA) scan, which will be used to determine muscle mass.

Experiment 2 participants will include individuals scheduled for either hip or knee replacement surgery or fracture repair surgery. Participants will be randomly assigned to one of two groups:

  • Group 1 participants will receive the antifungal drug ketoconazole, which is thought to reduce levels of the stress hormone cortisol.
  • Group 2 participants will receive placebo and standard rehabilitation care while in the hospital.

Participants will begin taking their assigned treatments the day prior to surgery; those with a hip fracture will take their assigned treatment at least 4 hours prior to surgery. The same procedures that occurred in Experiment 1 during surgery and hospitalization will be carried out during Experiment 2. The second metabolic study, however, will last only 1 hour and will include a standard clinical meal.

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for All Participants:

  • Scheduled for surgery because of osteoarthritis, avascular necrosis, fracture, or revision of total joint replacement in the hip or knee

Exclusion Criteria for All Participants:

  • Taking insulin, thiazolidinediones (TZD), or metformin
  • Kidney insufficiency, as indicated by serum creatinine of more than 2.0 mg/dl
  • Recently treated cancer other than basal cell carcinoma
  • Any other condition or event that would be considered as reason for exclusion by the study investigators
  • Pregnancy

Exclusion Criteria for Experiment 1 Participants:

  • Severe hypertension as indicated by requiring more than two drugs for blood pressure control
  • History of hypo- or hypercoagulation disorders, including individuals who have taken warfarin (Coumadin)
  • Atrial fibrillation, angina, or congestive heart failure

Exclusion Criteria for Experiment 2 Participants:

  • Liver disease or abnormal liver function tests
  • HIV infected
  • Active hepatitis
  • Any uncontrolled metabolic disease, including liver or kidney disease
  • Taking medications that use the cytochrome P450 pathway for metabolism and unable to discontinue their use for the duration of the study
  • Require certain medications. More information on this criterion can be found in the protocol.
  • Gastrointestinal absorption disorders that affect nutrient uptake
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00393848

Contacts
Contact: Arny Ferrando, PhD 501-526-5711 AFerrando@uams.edu
Contact: Scott Schutzler, RN 501-526-5734 seschutzler@uams.edu

Locations
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Arny Ferrando, PhD     501-526-5711     AFerrando@uams.edu    
Contact: Scott Schutzler, RN     501-526-5734     seschutzler@uams.edu    
Sub-Investigator: Richard Evans, MD            
Principal Investigator: Arny Ferrando, PhD            
Sub-Investigator: Johannes M Gruenwald, MD            
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Arny Ferrando, PhD University of Arkansas
  More Information

No publications provided

Responsible Party: University of Arkansas for Medical Sciences ( Arny A. Ferrando PhD )
Study ID Numbers: R01 AR052293, 70451, 1R01AR052293-01A2
Study First Received: October 27, 2006
Last Updated: September 1, 2009
ClinicalTrials.gov Identifier: NCT00393848     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):
Hip Replacement Arthroplasty
Hip Replacement Surgery
Hip Surgery
Hip Rehabilitation
Avascular Necrosis
Knee replacement surgery
Total knee arthroplasty

Additional relevant MeSH terms:
Anti-Infective Agents
Osteonecrosis
Osteoarthritis
Joint Diseases
Femur Head Necrosis
Fractures, Bone
Wounds and Injuries
Disorders of Environmental Origin
Rheumatic Diseases
Hip Injuries
Ketoconazole
Bone Diseases
Pharmacologic Actions
Hip Fractures
Necrosis
Femoral Fractures
Pathologic Processes
Musculoskeletal Diseases
Therapeutic Uses
Antifungal Agents
Arthritis
Leg Injuries

ClinicalTrials.gov processed this record on November 20, 2009